argenx SE (ARGX) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of February 28, 2026, argenx SE (ARGX) trades at a price-to-earnings ratio of 60.0x, with a stock price of $766.92 and trailing twelve-month earnings per share of $14.06.
The current P/E is roughly in line with its 5-year average of 64.4x. Over the past five years, ARGX's P/E has ranged from a low of 36.6x to a high of 92.2x, placing the current valuation at the 50th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, ARGX trades at a 153% premium to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, ARGX commands a significant premium over the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ARGX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Immunology and Inflammation Therapies peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
ARGXargenx SE | $47B | 60.0 | -Best | +348% |
TGTXTG Therapeutics, Inc. | $5B | 200.6 | -Best | +76% |
KNSAKiniksa Pharmaceuticals, Ltd. | $3B | 59.3 | -Best | +225% |
APLSApellis Pharmaceuticals, Inc. | $3B | 116.4 | -Best | +111% |
GLPGGalapagos N.V. | $2B | 5.9Lowest | -Best | +333% |
AUPHAurinia Pharmaceuticals Inc. | $2B | 6.8 | -Best | +5167%Best |
GYREGyre Therapeutics, Inc. | $711M | 164.8 | -Best | +104% |
RIGLRigel Pharmaceuticals, Inc. | $615M | 35.1 | -Best | +169% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $551.22 | $15.07 | 36.6x | -43% |
| FY2024 Q4 | $615.00 | $6.67 | 92.2x | +43% |
Average P/E for displayed period: 64.4x
See ARGX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARGX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ARGX vs AGIO
See how ARGX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ARGX stock overvalued or undervalued?
ARGX trades at 60.0x P/E, near its 5-year average of 64.4x. The 50th percentile ranking places valuation within normal historical bounds.
How does ARGX's valuation compare to peers?
argenx SE P/E of 60.0x compares to sector median of 23.7x. The premium reflects expected growth above peers.
What is ARGX's PEG ratio?
ARGX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2025.